DISPATCH / SAN FRANCISCO / HEALTH
Swing
Swing
Therapeutics.
The fibromyalgia clinic that fits in a pocket. Software that the FDA agrees is medicine.
The fibromyalgia clinic that fits in a pocket. Software that the FDA agrees is medicine.
It is a weekday morning in 2026 and somewhere in a kitchen in Pittsburgh, a 47-year-old woman with fibromyalgia is taking her medicine. The medicine is an app. The dose is 15 minutes. The pharmacy is the App Store. The bill goes to Highmark.
This is what Swing Therapeutics, Inc. has quietly built - a piece of software that the U.S. Food and Drug Administration has agreed, in writing, is the first prescription digital therapy ever cleared for fibromyalgia symptoms. It is called Stanza, and it is the rare thing in modern healthcare that does not arrive with a warning label about your liver.
The company is small. Twenty-two people, last we counted, mostly working remotely, headquartered in a building on Market Street where the elevator buttons still need to be pressed by a finger. The product is invisible. The implications are not.
The science behind Stanza is not new. Acceptance and Commitment Therapy - ACT, in the trade - has been used by behavioral therapists for decades to help patients with chronic pain decouple themselves from the catastrophizing thought loops that intensify their symptoms. The trick is that very few people who would benefit from ACT can actually access a therapist trained to deliver it. There are not enough hours in the week. There are not enough therapists in the country.
Mike Rosenbluth, the engineer-turned-CEO who founded Swing Therapeutics in 2019, looked at that gap and concluded that software was the answer - not because software is a substitute for human care, but because software is patient, scalable, and available at 3 a.m. when a flare wakes you up.
Stanza walks patients through daily modules of acceptance and commitment therapy, paced over roughly twelve weeks. Sessions are short. The interface is calm. There are no pop-ups celebrating streaks. The product is built on a piece of behavioral science that says: fighting pain makes it worse, and learning to coexist with it makes it smaller.
A prescription smartphone app delivering acceptance and commitment therapy to adults with fibromyalgia. FDA De Novo authorization, 2023. About 15 minutes a day. No side effects observed in clinical studies.
A telehealth clinic that prescribes Stanza alongside medication management and lifestyle coaching - the kind of integrated care that fibromyalgia patients almost never get from a single provider.
Through Swing Care or your own provider.
Sent electronically. Activate on your phone.
15-minute ACT sessions, paced over ~12 weeks.
Symptoms, function, quality of life - measured.
Stanza was studied in PROSPER-FM, a randomized, controlled Phase 3 trial whose results were published in The Lancet. The headline finding: patients who used Stanza reported clinically meaningful improvements in fibromyalgia symptoms compared to those who did not. The company also reports that 9 out of 10 patients preferred Stanza to medications alone.
That kind of evidence base is unusual in digital health, where the typical playbook has been to launch fast and worry about randomized trials later. Swing took the other route. The receipts are public.
Mike Rosenbluth starts Swing Therapeutics with a focus on chronic illness where digital intervention may be effective.
The agency formally flags Stanza as worth fast-tracking. The company also closes a $9M seed led by JAZZ Venture Partners.
JAZZ leads again. Proceeds fund the Phase 3 trial and the launch of the Swing Care telehealth clinic.
Stanza becomes the first FDA-cleared prescription digital therapy for fibromyalgia symptoms.
A major U.S. health plan adds reimbursement for Stanza - a real-world test of whether payers will treat software as medicine.
Additional growth capital reported, bringing total funding past $30M.
Fibromyalgia is the disease the medical system is least equipped to treat well. It is invisible on most imaging. It does not yield to a single biomarker. Patients are often told for years that what they are feeling is not really there, and then handed a prescription for something that takes the edge off but does not address the underlying central pain sensitization.
This is exactly the kind of disease, Swing argues, where a software-delivered behavioral therapy can do real work - not as a replacement for drugs, but as a non-drug option that finally has evidence behind it.
The company's bet is that the next decade of digital therapeutics will be built on this template: pick a disease where the standard of care is unsatisfying, run a real trial, get the regulatory clearance, and let the payer follow the evidence.
It is the same kitchen, the same woman, the same morning light. Her phone vibrates with the day's session. She opens the app. Fifteen minutes pass. She puts the phone down and starts her day.
What changed in this kitchen between the start of this story and its end is not dramatic. There is no medical drama playing out on a stretcher. Nobody is being wheeled into surgery. The medicine cabinet looks roughly the same as it did before. The difference is quieter. The difference is that the thing she does for her chronic pain, every morning, is something that the FDA has reviewed, that a randomized controlled trial has tested, that The Lancet has published, and that her insurer has agreed to pay for.
Swing Therapeutics did not cure fibromyalgia. It did something less heroic and probably more useful: it turned a piece of behavioral science into a daily prescription that fits in a pocket.
The medicine is a habit. The side effects are none. The pharmacy is a phone.